Jump to navigation Jump to search
Clinical data
AHFS/Drugs.comInternational Drug Names
ATC code
CAS Number
PubChem CID
E number{{#property:P628}}
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
Molar mass414.453 g/mol
3D model (JSmol)

WikiDoc Resources for Temocillin


Most recent articles on Temocillin

Most cited articles on Temocillin

Review articles on Temocillin

Articles on Temocillin in N Eng J Med, Lancet, BMJ


Powerpoint slides on Temocillin

Images of Temocillin

Photos of Temocillin

Podcasts & MP3s on Temocillin

Videos on Temocillin

Evidence Based Medicine

Cochrane Collaboration on Temocillin

Bandolier on Temocillin

TRIP on Temocillin

Clinical Trials

Ongoing Trials on Temocillin at Clinical Trials.gov

Trial results on Temocillin

Clinical Trials on Temocillin at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Temocillin

NICE Guidance on Temocillin


FDA on Temocillin

CDC on Temocillin


Books on Temocillin


Temocillin in the news

Be alerted to news on Temocillin

News trends on Temocillin


Blogs on Temocillin


Definitions of Temocillin

Patient Resources / Community

Patient resources on Temocillin

Discussion groups on Temocillin

Patient Handouts on Temocillin

Directions to Hospitals Treating Temocillin

Risk calculators and risk factors for Temocillin

Healthcare Provider Resources

Symptoms of Temocillin

Causes & Risk Factors for Temocillin

Diagnostic studies for Temocillin

Treatment of Temocillin

Continuing Medical Education (CME)

CME Programs on Temocillin


Temocillin en Espanol

Temocillin en Francais


Temocillin in the Marketplace

Patents on Temocillin

Experimental / Informatics

List of terms related to Temocillin

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]


Temocillin is a β-lactamase-resistant penicillin[1][2] introduced by Beecham, marketed by Eumedica Pharmaceuticals as Negaban. It is used primarily for the treatment of multiple drug-resistant, Gram-negative bacteria. It is a carboxypenicillin.[3]


Temocillin is a β-lactamase-resistant penicillin. It is not active against Gram-positive bacteria or bacteria with altered penicillin-binding proteins.

It is normally active against Moraxella catarrhalis, Brucella abortus, Burkholderia cepacia, Citrobacter species, Escherichia coli, Haemophilus influenzae, Klebsiella pneumoniae, Pasteurella multocida, Proteus mirabilis, Salmonella typhimurium, and Yersinia enterocolitica. It is also active against some Enterobacter species, Morganella morganii, and Serratia species. Temocillin has no useful activity against Acinetobacter species or Pseudomonas aeruginosa.

Its primary use is against Enterobacteriaceae, and in particular against strains producing extended-spectrum β-lactamase or AmpC β-lactamase.[4]


The common dose is 2 g intravenously every 12 hours. Theoretical reasons exist for giving temocillin as a continuous intravenous infusion in severe disease:[5] a single loading dose of 2 g is given intravenously followed by a 4-g infusion over 24 hours. Temocillin for intravenous injection is diluted in 20 ml of sterile water; it is diluted in less than 2.7 ml of sterile water when being prepared for intramuscular injection; the continuous infusion is diluted in 48 ml of sterile water for ease of administration (1 ml per half hour). To reduce pain, the intramuscular injection may be made up using sterile 1% lignocaine instead of sterile water.

Temocillin may be given to patients with impaired renal function. No adjustment needs to be made to the dose in mild to moderate renal impairment (creatinine clearance greater than 30 ml/min). Temocillin is cleared by haemodialysis, so in dialysis patients, the dose should be given after dialysis.

No oral preparation of temocillin is licensed.

Adverse effects

The undesirable effects of temocillin are those of any β-lactam antibiotic. In particular, it has been associated with angioedema and anaphylaxis in penicillin-allergic patients. Animal studies have not shown any induction of Clostridium difficile infection.[6] As with any other penicillin, convulsions can occur if very high doses are given.


Temocillin synthesis:[7]


  1. Andrews JM, Jevons G, Walker R, Ashby J, Fraise AP (July 2007). "Temocillin susceptibility by BSAC methodology". J. Antimicrob. Chemother. 60 (1): 185–7. doi:10.1093/jac/dkm179. PMID 17550891.
  2. Van Landuyt HW, Pyckavet M, Lambert A, Boelaert J (October 1982). "In vitro activity of temocillin (BRL 17421), a novel beta-lactam antibiotic". Antimicrob. Agents Chemother. 22 (4): 535–40. doi:10.1128/aac.22.4.535. PMC 183789. PMID 7181470.
  3. Chanal M, Sirot J, Cluzel M, Joly B, Glanddier Y (June 1983). "[In vitro study of the bacteriostatic and bactericidal activity of temocillin (BRL 17421)]". Pathol. Biol. (in French). 31 (6): 467–70. PMID 6348653.
  4. Livermore DM et al. (2006) Activity of temocillin vs. prevalent ESBL- and AmpC-producing Enterobacteriaceae from SE England. J Antimicrob Chemother. 2006 May;57(5):1012-4.
  5. De Jongh R et al. (2008) Continuous versus intermittent infusion of temocillin, a directed spectrum penicillin for intensive care patients with nosocomial pneumonia: stability, compatibility, population pharmacokinetic studies and breakpoint selection. J Antimicrob Chemother. 2008 Feb;61(2):382-8.
  6. Boon RJ; et al. (1985). "Studies with temocillin in a hamster model of antibiotic-associated colitis". Antimicrob Agents Chemother. 27 (6): 980–1. doi:10.1128/aac.27.6.980. PMC 180203. PMID 3875312.
  7. Template:Cite doi

Further reading